ReviewMaterials today. Bio2025
Cuproptosis-driven nanostrategies: Synergistic nanoplatforms for tumor microenvironment reprogramming and enhanced anticancer efficacy.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Mitochondria-targeted peptide-engineered bimetallic nanozymes enable ferroptosis-sensitized cuproptosis for melanoma therapy.Materials today. Bio · 2026Article
- From copper imbalance to immunometabolic remodeling: cuproptosis-related vulnerability and therapeutic hypotheses in autoimmune diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Metal ion-amplified phototherapy for tumors: Mechanisms, nanomaterial design, and synergistic strategies.Materials today. Bio · 2026Review
- Mechanisms and Applications of Manganese-Based Materials in Tumor Immunotherapy.Molecules (Basel, Switzerland) · 2026Review
- A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy.Materials today. Bio · 2026Article
- From Bench to Bedside: Multifunctional Nanoplatforms in the Fight Against Non-alcoholic Fatty Liver Disease.International journal of nanomedicine · 2026Review
- Targeting cuproptosis opens a new chapter of nanomedicine: a scientometric and graphical analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Cuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy.Frontiers in oncology · 2026Review
- Navigating Transition Metal-Dependent Cell Death: Mechanisms, Crosstalk, and Future Directions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuproptosis, a novel copper-dependent regulated cell death mechanism, represents a paradigm shift in oncology by exploiting unique copper dyshomeostasis mechanisms to combat intractable malignancies. While cuproptosis-based therapies hold transformative potential for diverse cancers, their clinical translation is hindered by inherent limitations, including suboptimal immunostimulatory efficacy, insufficient tumor specificity, and immunosuppressive crosstalk within the tumor microenvironment. Recent breakthroughs in nanotechnology have unlocked revolutionary strategies to address these challenges, with copper-based nanotherapeutic systems emerging as precision tools to amplify cuproptosis efficacy. Engineered nanosystems circumvent critical barriers of conventional small-molecule drugs, such as off-target toxicity and pharmacokinetic instability, by enabling spatiotemporal control of copper delivery, microenvironment remodeling, and synergistic activation of cell death cascades. This review systematically examines cutting-edge advances in nanomaterial design for potentiating cuproptosis, emphasizing three transformative frontiers: (1) combinatorial cell death modalities integrating cuproptosis with apoptosis, ferroptosis, or pyroptosis for amplified therapeutic cascades; (2) multimodal nanoplatforms coupling cuproptosis inducers with various treatment modalities to overcome resistance; and (3) precision-targeted delivery systems utilizing ligand/receptor engineering and stimuli-responsive materials for tumor-selective copper overload. Finally, further mechanistic insights into nanomaterial-triggered cuproptosis and its immunomodulatory consequences within tumor niches are critically evaluated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.